FDA Approves Juvmo, New Once-Daily Pill for Parkinson's Disease
2 reports, 1 independent
Updated Oct 14
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The Food and Drug Administration approved Juvmo, a new drug for Parkinson's disease based on research conducted by UVA Health scientists. Juvmo is available as a pill taken once per day, a significant change from earlier drugs in the class that required injections. The drug was pioneered by Richard B. Mailman, PhD, and involved research from Xuemei Huang, MD, PhD.
From news-medical.net
Why it matters
The approval of Juvmo introduces a new treatment option for Parkinson's disease, a condition affecting millions globally. This new medication could increase competitive pressure within the neurological drug market.
From news-medical.net
Who's involved
- FDARegulatory agency that granted approval for the new Parkinson's drug.
- Xuemei HuangUVA Health scientist whose research was foundational to the drug's approval.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.Keep exploring
The entities involved
- FDA
-
Xuemei Huang
researcher (ORCID 0000-0002-7112-6407)
Nothing else this week.
Related events
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Research advances have led to the approval of new therapies by the FDA.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- VDPHL01 and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.